Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07100080 · ClinicalTrials.gov registry record · Phase 2
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
A Phase 2 study of Non-Small Cell Lung Cancer, sponsored by Bristol-Myers Squibb.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 596
- Enrollment target
- 20
- Study locations
NCT07100080: Recruiting Phase 2 study of Non-Small Cell Lung Cancer, sponsored by Bristol-Myers Squibb.
NCT07100080 is a Phase 2 study of Non-Small Cell Lung Cancer that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 596 participants, roughly in line with the 651-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target. The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07100080, a Phase 2 study of Non-Small Cell Lung Cancer, is actively recruiting participants, sponsored by Bristol-Myers Squibb.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 596 participants
- Enrollment target
- 20
- Study locations
Study Summary
A Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy
Primary Outcome
Phase 2
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Cisplatin
- DRUG Pemetrexed
- DRUG Iza-bren
Study Locations (20)
New York
- Perlmutter Cancer Center at NYU Langone Hospital - Long Island - Mineola
- NYU Langone Health - New York
- Local Institution - 0158 - New York
- Local Institution - 0186 - Rochester
Oregon
- Local Institution - 0038 - Portland
- Local Institution - 0275 - Portland
- Local Institution - 0171 - Portland
California
- Local Institution - 0279 - Irvine
- Local Institution - 0154 - Orange
Florida
- Local Institution - 0085 - Gainesville
- Local Institution - 0142 - Pembroke Pines
Georgia
- Local Institution - 0270 - Atlanta
- Local Institution - 0143 - Columbus
Ohio
- University Hospitals Cleveland Medical Center - Cleveland
- Local Institution - 0284 - Columbus
Colorado
- Shaw Cancer Center - Edwards
Illinois
- Local Institution - 0153 - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 596 participants |
| Start Date | 2025-11-05 |
| Est. Completion | 2031-05-15 |
| Phase | Phase 2 |
What NCT07100080 shows while recruiting
NCT07100080 is an interventional study that assigns participants to a tested intervention. The registered 596 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 651-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target.
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 4 interventions - of which Carboplatin is the first listed.
NCT07100080 names 20 study sites across 11 states, led by New York, Oregon, California.
Frequently Asked Questions
What is clinical trial NCT07100080 about?
NCT07100080 is a clinical study titled "Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)". A Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy
What is the current status of trial NCT07100080?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 596 participants. The study started on 2025-11-05. Estimated completion is 2031-05-15.
What conditions does trial NCT07100080 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT07100080?
The interventions under investigation include: Carboplatin (DRUG), Cisplatin (DRUG), Pemetrexed (DRUG), Iza-bren (DRUG).
Who is sponsoring clinical trial NCT07100080?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07100080 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07100080's enrollment target sits among peer trials
596 60th of 454 higher than 395 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 2
-
A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02138734 · 596 participants · Phase 1
A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer
- NCT06797245 · 596 participants · NA
APPROVE Trial: Evaluating a Prescription Digital Therapeutic for Treatment of OAB in Women
- NCT05723198 · 595 participants · Phase 3
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
- NCT04701684 · 594 participants · NA
WE-TRUST (Workflow Optimization to Reduce Time to Endovascular Reperfusion for Ultra-fast Stroke Treatment)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI